Glutathione S-transferase M1 and T1 polymorphisms and the risk of mild hepatotoxicity induced by carbamazepine in a Tunisian population study

Chahra Chbili1*, Anis Hassine1,2, Neila Fatallah1, Manel Nouira1, Salma Naija2, Sofiene Ben Ammou2 and Saad Saguem1

Abstract

Background: The aim of this study was to evaluate whether the glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) null alleles may contribute to carbamazepine-induced hepatotoxicity.

Methods: A cross-sectional prospective study was conducted to identify the frequency distribution of GSTM1 and GSTT1 alleles in 129 Tunisian epileptic patients treated with carbamazepine. Null alleles were determined using a Polymerase Chain Reaction. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by standard methods.

Results: Our results showed that the frequencies of GSTM1 (−) null allele and GSTT1 null (−) allele were 74.4 and 17.8% respectively. The ALT and AST levels were elevated in 46 (35.7%) and 33 (25.6%) cases. The mean values of ALT and AST were approximately 1.32 and 3.61 times higher than the upper limit of normal levels, respectively. The values of ALT and AST were significantly higher in GSTM1 (−) allele than in GSTM1 (+) (p = 10−3 and 0.004, respectively). The level of ALT was significantly higher in combination of GSTM1 (−)/T1 (−) than in combined GSTM1 (−)/T1 (+) and combined GSTM1 (+)/T1 (−) (p = 0.2 and 0.03, respectively), and that of AST was significantly higher in combination of GSTM1 (−)/T1 (−) and in combination of GSTM1 (+)/T1 (−) than in combination of GSTM1 (+)/T1 (+) (p = 10−3 and 10−3, respectively).

Conclusions: Our findings suggest that the GSTM1 (−) allele may be considered as a key factor for the development of carbamazepine-induced hepatotoxicity. Results related to GSTT (−) allele and elevation in AST levels should be considered with caution as AST may be elevated in other pathophysiological conditions.

Keywords: Glutathione-S-transferase M1, Glutathione-S-transferase T1, Epilepsy, Genetic polymorphisms, Carbamazepine

Background

Carbamazepine (CBZ) is an effective drug used for epilepsy, trigeminal neuralgia and many psychiatric disorders [1]. Although considered as a well tolerated anti-epileptic drug, several adverse drug reactions to CBZ may occur including hypersensitivity syndrome, hematotoxicity and hepatotoxicity [2, 3]. Severe CBZ-induced hepatotoxicity is exceptional. Elevation in hepatic enzymes is reported in almost 22% of CBZ-treated patients [4]. Adverse effects to CBZ have been attributed to reactive metabolites of the drug [3, 5]. In fact, in the liver, CBZ is oxidized to its major metabolite, the 10,11-epoxy-carbamazepine (CBZ-E) [6, 7] and to additional metabolites CBZ-arene oxide and CBZ iminoquinone by the cytochrome P450 enzymes [3]. Glutathione S-transferases (GST) are enzymes involved in phase II reactions and playing a key role in detoxifying drugs and xenobiotics. The implication of the metabolites of
CBZ has been suggested to induce adverse-drug reactions, cytotoxicity, and also genotoxicity [3, 5].

Both Glutathione S-transferase class mu (GSTM1) and class theta (GSTT1) are involved in reactions of glucoc conjugation of the main metabolite and also in the detoxification of toxic metabolites of CBZ [3, 7–9]. Null alleles of the GSTM1 and GSTT1 resulting on a deletion of the entire genes, lack any functional enzyme activity and fail to express the protein. Therefore, functional polymorphisms in the genes of GSTM1 and GSTT1 enzymes may lead to an increased risk for CBZ-induced adverse effects, including hepatotoxicity. Among ethnic groups, GSTM1 and GSTT1 null allele frequencies are varying from 23 to 62% respectively [10–13]. Drug-induced hepatotoxicity is often unpredictable and may result in a transient elevation in transaminase enzymes, but may be fatal leading to acute liver injury. Many reports have investigated the involvement of GSTs null allele in the occurrence of hepatotoxicity with anti-tubercular drugs, in alzheimer’s disease and with troglitazone therapy [14]. In CBZ-induced hepatotoxicity, very few reports have investigated the influence of GSTs alleles in the detoxification of toxic metabolites [14].

To the best of our information, no previous reports in tunisian population nor in subsaharian African population have focused on the effects of GSTM1 and GSTT1 null alleles in elevations of liver enzymes in CBZ-treated patients. Therefore, in our study, the influence of GSTM1 and GSTT1 null alleles in elevation of transaminase enzyme levels among Tunisian epileptic patients treated with CBZ has been investigated.

Methods

Subjects

Study design

A cross-sectional prospective study has been conducted in the Department of Neurology “Sahloul Hospital of Sousse Tunisia”, from September 2010 to July 2015 (Fig. 1).

Inclusion criteria

- Epileptic patients aged between 14 and 80 years old on monotherapy by CBZ.
- At least 1 month of obtaining the maintenance dose of CBZ.
- Pretherapeutic liver function tests in normal ranges.
- Hepatotoxicity was defined as raised levels of transaminase above the upper limit of normal range (ULN) at least once during the period of study.

Before initiation of CBZ therapy, a complete cell count and hepatic function test were performed. Then, in the first month, two tests were performed once a week and periodically (every 3 months) as
recommended [15]. The ULN for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 31 IU/L and 34 IU/L respectively.

Non-inclusion criteria

- Previous chronic or acute liver disease,
- Presence of serological evidence of infection with hepatitis viruses.
- Chronic renal disease.
- History of chronic alcohol intake and/or herbal consumption.
- Drug consumption interfering with the metabolism of CBZ or with liver function tests.

Genotyping

Extraction of genomic DNA was performed from blood samples using the Wizard Genomic DNA Purification Kit (cat. *A1120) (Promega, Madison, USA).

The genotyping of GSTM1 and GSTT1 was performed using a previously described Polymerase Chain Reaction (PCR) [16].

In our study, the deleted gene of GSTM1 is termed GSTM1 null allele or GSTM1 (−). Heterozygotes [GSTM1(+/−)] and the homozygous wild type, GSTM1(+/+)] are designed GSTM1 (+). As for the GSTT class, deletion of the entire gene is termed GSTT1(−). While heterozygotes [GSTT1(+/−)] and the homozygous wild type GSTT1(+/+)] are designed GSTT1 (+).

Phenotype analysis

An analysis of plasma samples were performed in the Laboratory of Metabolic Biophysics, Professional Toxicology and Applied Environmental, Department of Biophysics, Medicine Faculty of Sousse, Sousse, Tunisia. Dosage of CBZ and CBZ-E was conducted using previously described high performance liquid chromatography [17].

Serum alanine aminotransferase and aspartate aminotransferase were measured by standard methods adopted by Biochemical Laboratory of University Hospital Sahloul.

Statistical analysis

The mean values of the ALT and AST in epileptic patients were compared according to the different types of genetic polymorphisms of GST by applying the test U Mann–Whitney. Using the Kolmogorov–Smirnov test to a sample, the variables studied follow a non-normal distribution where recourse to the use of non-parametric test (U-test Mann–Whitney).

The correlation between levels of transaminases and the doses per mg/kg/day or the plasma concentration of carbamazepine were studied by Pearson’s correlation test.

Association between genotype frequencies of GSTM1/ T1 allele distribution and carbamazepine-induced mild hepatotoxicity was analyzed by calculating odds ratios (OR) and 95% confidence intervals (CLs). Statistical analysis was performed using the SPSS software package. A probability of $p < 0.05$ was considered statistically significant.

Ethical considerations

Ethics committee approval and patient consent was obtained for our study.

The local ethical committee of Sahloul University hospital has approved this study. Informations were made anonymous after the collection of the data and blood samples.

Results

Our study included 129 epileptic Tunisian patients (55 males and 74 females). Almost 54.68% suffered from focal seizures with or without secondary generalization (71 patients), 37.5% had generalized tonic-clonic seizures (48 patients) (Table 1). Patients were on CBZ therapy for 28.16 months (range: 18–36 months). Monitoring for epilepsy was performed for 3 years on average.

In our study, frequency distribution of the null allele of GSTM1 (GSTM1-) and the null allele of GSTT1 (GSTT-) were 74.4 and 17.8%, respectively. The ALT and AST were elevated in 35.7% (46 cases: 30 males /16 females) and 25.6% (33 cases: 22 males / 11 females). The mean levels of ALT and AST was 49 ± 6.44 and 112 ± 10.74, respectively.

A 1 mg/body weight/day increase of CBZ maintenance dosages (mg/kg/day) conferred OR of 1.004 (95% CI: 0.89–1.12; $p = 0.95$) and 0.99 (95% CI: 0.88–1.12; $p = 0.91$) on the elevation in ALT and AST levels respectively; while a 1 $μg/mL$ increase of plasma carbamazepine concentration conferred OR of 1.062 (95% CI: 0.92–1.22; $p = 0.40$) and 1.14 (95% CI: 0.97–1.33; $p = 0.11$) on the elevation in ALT and AST levels, respectively (Table 2). Neither the dosage of CBZ per body weight nor the plasma CBZ concentrations were associated with the ALT and AST

| Table 1 | Clinical detail in epileptic patients |
|---------|--------------------------------------|
| Total number of patients studied | 129 |
| Seizure type (partial/generalized) | 71/48 |
| Epilepsy type N (%) (Symptomatic/Cryptogenic) | 48/81 |
| Sex (M/F) | 55/74 |
| Age (years) | 38.26 ± 17 |
| Weight (kg) | 63.3 ± 7.6 |
levels. Levels of ALT and AST seem to not be affected by genders and age.

ALT and AST values were significantly higher in GSTM1 null allele (−) than in GSTM1 (+) \((p = 10^{-3}\) and 0.004, respectively) (Table 3). Concerning GSTT1, these values were not influenced by GSTT1(−). The results concerning the effects of the combinations of GST genotypes on the corresponding values of transaminases was significantly different (Table 2). The level of ALT was significantly elevated in GSTM1(−)/T1(−) and GSTM1(−)/T1(+) than in GSTM1(+)/T1(+) \((p = 0.03\) and 0.2, respectively). The level of AST was significantly higher in GSTM1(−)/T1(−) and GSTM1(+/)+T1(−) than in GSTM1(−)/T1(+) \((p = 10^{-3}\) and 10^{-3}, respectively).

The distribution of GST alleles and the increase of transaminases are shown in Table 4.

The GSTM1 null genotype frequency was 65.1 and 91.3% in patients with normal and elevated levels of ALT, respectively (OR: 5.64; 95% CI: 1.70–20.60; \(p = 0.0022\)), and was 66.7 and 97% in cases with normal and elevated levels of AST, respectively (OR: 11; 95% CI: 1.56–77.37; \(p = 0.0013\)). On the contrary, no difference between the frequency of the GSTT1 (−) in the cases with normal or elevated ALT and AST, respectively was found (OR: 0.95; 95% CI: 0.33–2.68; \(p = 0.88\)) and (OR: 1.73; 95% CI: 0.59–5.01; \(p = 0.39\)). So, levels of transaminases were influenced by the genotype GSTM1 (−) and seem to not be affected by GSTT1 (−).

The frequency of GSTM1 (−)/T1 (−) \((16.41\%)\) was significantly higher than that of the GSTM1(+/)+T1(+) \((3.13\%)\) in cases with elevated ALT \((OR: 0.18; 95\%\ CI: 0.04–0.75; \(p = 0.014\)). The frequency of GSTM1 (−)/T1 (−) \((16.41\%)\) was also significantly higher than that of the GSTM1(+/)+T1(+) \((1.56\%)\) in cases with elevated AST \((OR: 0.08; 95\%\ CI: 0.01–0.45; \(p = 0.0012\)).

**Table 3** Mean values of ALT and AST in each genotype

| ALT (IU/l) | p-value* | AST (IU/l) | p-value* |
|-----------|----------|------------|----------|
| GSTM1 genotype (n) |          |            |          |
| Null (96) | 37.5 ± 5.716 | 10^{-3} | 35.03 ± 11.8 | 0.004 |
| Present (33) | 30.93 ± 6.025 |            | 28.81 ± 4.35 |          |
| GSTT1 genotype (n) |          |            |          |
| Null (23) | 34.47 ± 8.36 | 0.27 | 35.26 ± 8.20 | 0.37 |
| Present (106) | 36.11 ± 5.96 |            | 33.05 ± 11.21 |          |
| Combination of GSTM1/GSTT1 (n) |          |            |          |
| M1+/T1− (19) | 32.74 ± 6.87 | 28.42 ± 5.57 |          |
| M1+/T1− (8) | 33.87 ± 10.66 | 53.62 ± 23.91 | 10^{-3} |
| M1−/T1+ (66) | 35.86 ± 3.88 | 0.02* | 29.31 ± 4.57 |          |
| M1−/T1− (35) | 37.88 ± 8.28 | 0.03* | 39.71 ± 8.47 | 10^{-3} |

Null hypothesis H0: no differences between the mean values of ALT and AST in each GSTM1(−) and GSTT1(−), combined GSTM1(−) and GSTT1(−) and mean values of ALT and AST

*p-value* by Mann-Whitney U test

*Compared with M1+/T1+

Bold entries indicate significance.

**Table 2** Relationship between mean dosage of CBZ per body weight, mean plasma CBZ concentrations and ALT/AST levels

| Mean dosage (mg/kg/day) | p-value | OR* (95% CI) | ALT | p-value | OR* (95% CI) |
|------------------------|---------|--------------|-----|---------|--------------|
| Normal (n) 83 | 7.92 ± 3.80 | 0.94 | 1.004 (0.89–1.12) | 7.96 ± 2.06 | 0.91 | 0.99 (0.88–1.12) |
| Elevated (n) 46 | 6.25 ± 2.70 | 0.40 | 1.062 (0.89–1.22) | 6.18 ± 2.77 | 0.11 | 1.14 (0.97–1.33) |
| Mean plasma carbamazepine concentrations (µg/mL) | 6.25 ± 2.70 | 0.39 | 1.062 (0.89–1.22) | 6.18 ± 2.77 | 0.11 | 1.14 (0.97–1.33) |

H0: no difference between mean dosage of CBZ per body weight, mean plasma CBZ concentrations and ALT/AST levels

*p<0.05 is significant

Discussion

We performed a study of association between null alleles of GSTM1 and GSTT1 and risk of mild elevation of liver enzymes in Tunisian epileptic patients treated with CBZ on monotherapy. The GSTM1 and GSTT1 null alleles (GSTM1(−) and GSTT1(−)) consisting on a deletion of the complete genes and resulting in a lack of active enzymes are the most common polymorphisms in these genes. The frequencies of GSTM1 and GSTT1 deficiency vary from 23 to 62% respectively \([10–12]\). In Tunisian population, GSTM1 null allele frequency was of 34.6% and GSTT1 null allele frequency was of 16.6%. The frequency of double deletion of both GSTM1 and GSTT1 was of 4.82 \([18]\).

In another genetic study of the association of GSTM1 and GSTT1 polymorphisms reported in three Arab populations (Bahraini, Lebanese and Tunisian), including 186 Tunisian healthy subjects, the prevalence of GSTT1 null allele was of 37.1%, GSTM1 null allele was of 63.4% and deleted allele of both genes was found in 21.0% of Tunisians \([19]\).

In our population study, the frequency of patients carrying null alleles of GSTM1 and GSTT1 were consistent with these results.

The GSTM1 (−) allele was associated with elevated levels of both ALT and AST. It seems to affect the levels of transaminases in our population study and to be a risk factor for mild hepatotoxicity induced by CBZ. As for the GSTT1 (−) allele, it seems not to influence the ALT and AST levels. Whereas the combination of GSTM1 (+)/GSTT1 (−) alleles seems to affect the levels
of AST. In fact, the GSTM1 (−) allele is rather significantly associated with an increase in ALT levels and in AST levels respectively than the GSTT1 (−) allele. Our results are consistent with those of Ueda et al. [20] who reported that GSTM1 (−) allele was related with the risk of mild hepatotoxicity induced by CBZ in Japanese population. As far as we know, this is the first study reporting an association between the GSTM1 (−) allele and the increasing values of transaminases in Tunisian and subsaharian population.

Many reports have associated the GST null alleles, leading to a lack of functional protein, with an increase susceptibility to several diseases, such as cancer, cardiovascular, epilepsy, schizophrenia and hepatotoxicity [16, 21–24]. The reactive metabolites of drugs causing drug toxicity are detoxified by GST enzymes. So, an inherited weakness of drug eliminating capacity related to a null GST alleles may enhance toxic drug-induced adverse events [3, 5, 7, 10, 25]. A 2-fold ULN increased risk of elevation levels of ALT has been reported in individuals exhibiting the GSTM1 (−) allele among patients treated with isoniazid, rifampicin and pyrazinamide for pulmonary tuberculosis [26, 27]. Simon and colleagues [28] showed that 72% of patients carriers of GSTM1(−)/T1(−) alleles have at least three times elevated ALT levels among Alzheimer’s disease. Watanabe and colleagues [27] found higher risk of hepatotoxicity-induced by troglitazone in patients with GSTM1 (−)/T1(−) alleles.

Our study found that the GSTM1 (−) allele, especially when combined with GSTT1 (−) allele, may be a genetic factor associated with the increased risk of hepatotoxicity. In many reports, toxic effects of drugs have been attributed to the formation of chemically reactive metabolites [3, 5]. The metabolites of CBZ, such as 10,11- epoxy-carbamazepine (CBZ-E), arene oxide (s) and iminoquinone (s), may be associated with drug hypersensitivity reactions, cytotoxicity and genotoxicity [3, 5, 7, 25]. The CBZ-E is a chemically reactive metabolite and may be converted into electrophilic reactive intermediate with glutathione (GSH) [26]. So, GST may play a role in the overall covalent binding potential of CBZ-E with liver microsomes and polymorphisms may be responsible for liver-toxicities [29].

In our study, neither the dosage of CBZ per body weight nor the plasma CBZ concentrations were associated with transaminase levels. It is evidence that CBZ-induced hepatotoxicity is dose-independent and carbamazepine toxicity seems to not be correlated with CBZ plasma concentration. It may be rather induced by allergic reactions [3].

GSTM1 seem to affect ALT levels whereas GSTT1 seem to be related to AST levels. These results can be explained, almost partly, by the distribution of transaminases and the GST enzymes. While ALT is mainly distributed in the liver, AST is present in the liver, red blood cells and muscle. Consequently, ALT is therefore considered to be a more accurate sign of liver damage than AST. In addition, GSTM1 is widely expressed in the liver, and GSTT1 is principally expressed in erythrocytes [10, 13]. Consequently, the ALT levels may be more affected by GSTM1 (−) allele while AST may be more susceptible to GSTT1 (−) allele. Thus, our findings suggest that the GSTM1 (−) allele may be considered as a key factor for the development of carbamazepine-induced hepatotoxicity.

However, our findings should be considered with caution. Many limits of our study should be mentioned. First, our population study number is small. Although we tried to be exhaustive and to include all the patients

| Table 4 | Distribution of GSTM1 and GSTT1 alleles in patients with elevated or normal levels of ALT and AST |
|---------|-------------------------------------------------|
|         | ALT Normal | Elevated | p-value | OR* (95% CI) | AST Normal | Elevated | p-value | OR* (95% CI) |
| GSTM1 genotype (n) | | | | | | | | |
| Null | 54 | 42 | **0.0022** | 5.64 (1.70–20.60) | 64 | 32 | **0.0013** | 11 (1.56–77.37) |
| Present | 29 | 4 | | | 32 | 1 | | |
| GSTT1 genotype (n) | | | | | | | | |
| Null | 15 | 8 | 0.88 | 0.95 (0.33–2.68) | 15 | 8 | 0.39 | 1.73 (0.59–5.01) |
| Present | 68 | 38 | | | 81 | 25 | | |
| Combination of GSTM1/GSTT1 | | | | | | | | |
| M1+/T1+ | 15 | 4 | 1.0 | | 17 | 2 | 1.0 | |
| M1+/T1- | 5 | 3 | 0.68 | 0.44 (0.05–3.74) | 0 | 8 | 0.99 | 4(Undefined) |
| M1−/T1+ | 48 | 18 | 0.80 | 0.71 (0.17–2.73) | 64 | 2 | 0.45 | 3.76 (0.34–41.37) |
| M1−/T1- | 14 | 21 | **0.014** | **0.18** (0.04–0.75) | 14 | 21 | **0.0012** | **0.08** (0.01–0.45) |

Null hypothesis (H0): no differences between GSTM1 and GSTT1 alleles in patients with elevated or normal levels of ALT and AST
p < 0.05 is significant
Bold entries indicate significance
responding to our inclusion criteria, our small sample size just suggests a trend to possible correlation between GSTM1 (−) allele and elevation in ALT and AST levels. Additional reports would be indispensable for proving our results in a larger scale.

Second, investigations in patients with elevated AST levels were not performed to rule out other susceptible causes. Moreover, single laboratory liver test may be of little value.

Conclusions

An association between GST genotyping and a possible effect in transaminases in an epileptic population study on CBZ in monotherapy was attempted. Our results showed a possible correlation between GSTM1 (−) genotype and elevation in ALT and AST levels. GST null allele may be a risk factor for mild hepatotoxicity in Tunisian epileptic patients. Further studies including a larger sample sizes would be necessary for proving our results.

Abbreviations

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CBZ: Carbamazepine; CBZ-E: 10,11-epoxy-carbamazepine; CL: Confidence intervals; GSH: Glutathione; GSTM1 (−): Null allele of the GSTM1; GSTM1: Glutathione S-transferase M1; GSTT1 (−): Null allele of the GSTT1; GSTT1: Glutathione S-transferase T1; HPLC: High-performance liquid chromatography; OR: Odds ratios; PCR: Polymerase Chain Reaction; SD: Standard deviation; ULN: Upper limit of normal range.

Acknowledgements

We thank all the staff of the Laboratory of Metabolic Biophysics, Professional Toxicology and Applied Environmental Laboratory (LR12ES02), Medicine Faculty of Sousse, Tunisia for their help and assistance.

Funding

This study was supported by the “Higher Education and Scientific Research Ministry” in Tunisia.

Availability of data and materials

The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

CC performed the experiments analytical studies and wrote the manuscript; FN wrote the manuscript; HA conducted and performed the periodic clinical monitoring; SS planned the study, NM checked the final form of the manuscript, NS improved the English of the manuscript and BAS read and approved the final manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the local ethical committee. A written informed consent was obtained from each study participant before interview and blood collection for genetic analyses. For those under the age of 18, a consent was obtained from their parents. All information regarding the participants was made anonymous after the collection of the data and blood samples.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Metabolic Biophysics, Professional Toxicology and Applied Environmental Laboratory, Department of Biophysics, Medicine Faculty of Sousse, Sousse University, Avenue Mohamed Karoui, 4002 Sousse, Tunisia. 2Neurology Department of Central Hospital University (CHU), Sousse University, 4002 Sousse, Tunisia.

Received: 13 April 2017 Accepted: 3 January 2018

Published online: 09 March 2018

References

1. Ek O, Ban E, Woo JS, Kim CK. Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography. Anal Bioanal Chem. 2006;386(6):1931–6.
2. Brodie MJ, Dichter M. Antiepileptic drugs. N Engl J Med. 1996;334(3):168–75.
3. Kalapos MP. Carbamazepine-provoked hepatotoxicity and possible aetopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. Adverse Drug React Toxicol Rev. 2002;21(3):123–41.
4. Harden CL. Therapeutic safety monitoring: what to look for and when to look for it. Epilepsia. 2000;41:37–44.
5. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos. 2002;30(11):1170–5.
6. Breton H, Cocciglio M, Bressolle F, Peyriere H, Blavac JP, Hillabe-Buyt D. Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2005;828:80–90.
7. Bu HZ, Kang P, Deese AJ, Zhao P, Pool WF. Human in vitro glutathionyl and protein-adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos. 2005;33:1920–4.
8. Blettislon L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet. 1986;11:177–98.
9. DeBethizy JD, Hayes JR. Metabolism. A determinant of toxicity. In: Hayes AW, editor. Principles and methods of toxicology. 2nd ed. New York: Raven Press; 1988. p. 29–66.
10. Hayes JD, Flanagan JU, Jossey JR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.
11. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, Katoh T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003;129:355–60.
12. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis. 1994;15:1077–81.
13. Eaton DL, Bannmler TK. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci. 1999;49(2):156–64.
14. Levy M, Goodman MW, Van Dyne BJ, Sumner HW. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med. 1981;95(1):64–5.
15. Lévy-Chavagnat D. Stratégies de traitement des syndromes épileptiques. Revue Neurologique. 1994;150:21–5.
16. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis. 1994;15:1077–81.
17. Eaton DL, Bannmler TK. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci. 1999;49(2):156–64.
18. Levy M, Goodman MW, Van Dyne BJ, Sumner HW. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med. 1981;95(1):64–5.
19. Lévy-Chavagnat D. Stratégies de traitement des syndromes épileptiques. Actual Pharm. 2008;475:10–6.
20. Chibli C, Bichiri F, Ben Fedj M, Saguen WM, Ben Amor S, Ben Ammou S, Saguen WM. Effects of glutathione S-transferase M1 and T1 deletions on epilepsy risk among a Tunisian population. Epilepsy Res. 2014a;108:168–73.
21. Chibli C, Bichiri F, Ben Fedj M, Saguen WM, Ben Amor S, Ben Ammou S, Saguen WM. Effects of glutathione S-transferase M1 and T1 deletions on epilepsy risk among a Tunisian population. Epilepsy Res. 2014b;108:168–73.
22. Gara S, Abessi M, Bendjermou K, Abdennebi M, Guemira F. Deletion polymorphism of glutathione S-transferase M1 and T1 genes in three distinct Arab populations. Dis Markers. 2011;31(5):311–6.

Springer
20. Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, Nakagawa K. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics. 2007;8:435–842.

21. Gravina P, Spoletrini I, Masini S, Valenti A, Vanni D, Paladini E, Bossù P, Caltagirone C, Federici G, Spalletta G, Bernardini S. Genetic polymorphisms of glutathione S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. Psychiatry Res. 2011;187(3):454–6.

22. Cotton SC, Sharp I, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol. 2000;151:7–32.

23. Habdous M, Siest G, Herbell B, Vincent-Viny M, Visvikis S. Polymorphismes des glutathion S-transférases et pathologies humaines: bilan des études épidémiologiques. Ann Biol Clin. 2004;62:15–24.

24. Martin NJ, Collier AC, Bowen LD, Pritsos KL, Goodrich GG, Arger K, Cutter G, Pritsos CA. Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. Mutat Res. 2009;674(1–2):93–100.

25. Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol. 1992;43:1675–82.

26. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 null mutation. J Gastroenterol Hepatol. 2001;16(9):1033–7.

27. Watanabe I, Tomita A, Shimizu M, Sugawara Y, Yasumoto H, Koishi R, Takahashi T, Miyoshi K, Nakamura K, Izumi T, Matsushita Y, Furukawa H, Harayama H, Koga T. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2003;73(3):435–55.

28. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, Jaillon P. Combined glutathione S-transferases M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000;67(4):432–7.

29. Chbili C, Fathallah N, Nouira M, Laouani A, Hassine A, Ben Amor S, Ben Ammou S, Saguem S. Effects of glutathione S-transferase M1 and T1 deletions on carbamazepine metabolism among a Tunisian population. Genes Genomics. 2015;37(12):991–7.